精彩内容近日，国家药监局官网显示，浙江高跖医药的4类仿制药艾拉莫德片获批上市、视同过评，为公司首款风湿病治疗药。在中国三大终端六大市场，艾拉莫德片2024-2025Q1~Q3销售额均超过17亿元，同比增长25.28%和29.69%。来源：米内网项目进度数据库艾拉莫德片是一种新型的改善病情抗风湿病药物，具有抗炎、抑制免疫球蛋白生成、抑制炎性因子产生、抗骨吸入和促骨形成等作用，适应于活动性类风湿关节炎...
Source Link精彩内容近日，国家药监局官网显示，浙江高跖医药的4类仿制药艾拉莫德片获批上市、视同过评，为公司首款风湿病治疗药。在中国三大终端六大市场，艾拉莫德片2024-2025Q1~Q3销售额均超过17亿元，同比增长25.28%和29.69%。来源：米内网项目进度数据库艾拉莫德片是一种新型的改善病情抗风湿病药物，具有抗炎、抑制免疫球蛋白生成、抑制炎性因子产生、抗骨吸入和促骨形成等作用，适应于活动性类风湿关节炎...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.